About Us
At Bantam Pharmaceutical, we are developing novel, first-in-class oral small molecule therapeutics for difficult-to-treat hematological and solid tumors.
Our Strategy
We are leveraging our science across two workstreams:
- BTM-3566: We are progressing our lead candidate into the clinic
- Discovery: We are uncovering other potential small molecules with applications in oncology
Our strategy will enable us to develop a pipeline of future indications in selected solid and hematological tumors, opening the door to new compounds and patient populations experiencing severe unmet need.
Our Story
We are a private biotechnology company based in Research Triangle Park, North Carolina, USA.
BANTAM FOUNDED
Bantam founded based on acquired Harvard IP
COMPANY PIVOTS
Company switches focus to mitochondrial dynamics, as new insights provide our direction for the future
BTM-3566 IDENTIFIED
BTM-3566 identified as our first clinical candidate, with an initial focus in lymphoma
CMC CAMPAIGN
CMC campaign and initiation of IND enabling studies
MOVE TO IND
Ph 1a/1b with evidence of clinical efficacy
INITIATE FIRST CLINICAL TRIAL
BTM-3566 phase 1 study underway